Screener Summaries Updates Institutions Sign In More Updates › Other Events › AIM Other Events · Jun 15, 2026
AIM ImmunoTech Inc. received a letter from NYSE Regulation on June 12, 2026, confirming the company has regained… AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc. received a letter from NYSE Regulation on June 12, 2026, confirming the company has regained compliance with all NYSE American LLC continued listing standards, specifically resolving deficiencies under Section 1003(a)(i), (ii), and (iii). The company's trading symbol will no longer carry the "below compliance" indicator. AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies.
More from AIM ImmunoTech Inc. AIM ImmunoTech releases investor presentation highlighting Ampligen opportunity in pancreatic cancer Nov 5, 2026 AIM ImmunoTech Inc. converted approximately $400,000 of its outstanding Promissory Note into 1,749,434 shares of… Sep 14, 2026 AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $450,000… Sep 10, 2026 AIM ImmunoTech Inc. converted approximately $1,224,341 of outstanding debt under a Promissory Note dated February 16… Sep 4, 2026 AIM ImmunoTech Inc. entered into a securities purchase agreement on June 9, 2026, to conduct a registered direct… Jun 11, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
